Carlo Gambacorti-Passerini

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Carlo Gambacorti-Passerini

Carlo Gambacorti-Passerini (born 26 August 1957) is an Italian oncologist and hematologist known for his contributions to cancer research. He is Professor of Internal Medicine and Hematology at the University of Milan Bicocca in Italy and Director of the Clinical Research Unit at S. Gerardo Hospital, Monza, Italy. He was Senior Investigator and Head of the Oncogenic Fusion Proteins Unit at the National Cancer Institute, Milan Italy from 1990 to 2003, and Professor of Oncology and Hematology at McGill University, Montreal, Quebec, Canada, from 2004 to 2007.

His main scientific contribution relates to the preclinical and clinical development of imatinib.[1] His publications between 1997 and 2000 are among the earliest original reports on this revolutionary drug. Specifically, he showed that apoptosis, or programmed cell death, was the predominant mechanism through which imatinib eliminates leukemic cells, that leukemic animals could be cured using imatinib, and that resistance to imatinib could be mediated by gene amplification of BCR-ABL1.

Dr. Gambacorti-Passerini is the Chairman of the ILTE (Imatinib Long Term side Effects) study,[2] an independent clinical study aimed at assessing the long-term effects of imatinib in 948 CML patients worldwide, which showed for the first time that CML patients in remission have a normal life expectancy.[3] From 2006 to 2011 Dr. Gambacorti-Passerini was the first researcher to develop at preclinical and clinical level another drug for CML named bosutinib.

He is also the first researcher who (in June 2010) successfully treated a patient affected by ALK+ lymphoma with an ALK inhibitor (crizotinib).[4][5][6]

In 2012 Dr. Gambacorti-Passerini discovered SETBP1 as a novel oncogene and identified specific mutations of this gene in patients affected by atypical Chronic Myeloid Leukemia (aCML).[7]

References[edit]

  1. ^ Gambacorti-Passerini, C (2008). "Part I: Milestones in personalised medicine--imatinib". Lancet Oncology. 9 (600): 600. PMID 18510992. doi:10.1016/S1470-2045(08)70152-9. 
  2. ^ "ILTE study page". Retrieved 2012-04-28. 
  3. ^ Gambacorti-Passerini, C; Antolini, L; Mahon, F-X; et al. (2011). "Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib". J.Natl.Cancer Inst. (103): 553–561. 
  4. ^ Gambacorti-Passerini C et al. "Clinical Activity of Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients". 2010 Annual Meeting of the American Society of Hematology, Orlando, Florida
  5. ^ Gambacorti-Passerini, C; Messa, C; Pogliani, EM (2011). "Crizotinib in Anaplastic Large Cell Lymphoma". New Engl. J. Med. 364 (8): 775–776. PMID 21345110. doi:10.1056/nejmc1013224. 
  6. ^ Gambacorti Passerini, C; Farina, F; Stasia, A; Redaelli, S; Ceccon, M; Mologni, L; Messa, C; Guerra, L; Giudici, G; et al. (2014). "Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients". J Natl Cancer Inst. 106 (2): djt378. PMID 24491302. doi:10.1093/jnci/djt378. 
  7. ^ Piazza, R; Valletta, S; Winkelmann, N; Redaelli, S; Spinelli, R; Pirola, A; Antolini, L; Mologni, L; Donadoni, C; et al. (2013). "Recurrent SETBP1 mutations in atypical chronic myeloid leukemia". Nat Genet. 45 (1): 18–24. PMC 3588142Freely accessible. PMID 23222956. doi:10.1038/ng.2495.